PRSS30P: A Potential Drug Target and Biomarker (G124221)

Target Name: PRSS30P

NCBI ID: G124221

PRSS30P

Other Name(s): Serine protease 30, pseudogene | serine protease 30, pseudogene | Disp | TMPRSS8 | TMPRSS8P

PRSS30P: A Potential Drug Target and Biomarker

Protease serine 30 (PRSS30) is a protein that is expressed in various cell types of the human body. It is a member of the serine proteases family 30 and is characterized by its unique molecular structure and biology. PRSS30 is known to play a critical role in the regulation of cell signaling pathways, including the TGF-β pathway. This protein has also been shown to be involved in the development and progression of various diseases, including cancer. As a result, PRSS30 has emerged as a promising drug target and biomarker.

The TGF-β pathway is a critical signaling pathway that regulates cell growth, differentiation, and survival. It is involved in the development and maintenance of tissues and organs, as well as in responding to external stimuli, such as growth factors. The TGF-β pathway is activated by the presence of TGF-β ligands, which include various proteins, such as PRSS30.

PRSS30 is a 21-kDa protein that is expressed in various cell types of the human body, including muscle, liver, and cancer cells. It is characterized by its unique molecular structure, which consists of a catalytic active site and a hydrophobic tail. The catalytic active site is the site where PRSS30 performs its catalytic function, which involves the cleavage of other proteins. The hydrophobic tail is responsible for the stability and localization of the protein in the cell.

PRSS30 has been shown to be involved in the regulation of TGF-β signaling pathways. It has been shown to interact with various TGF-β ligands, including the protein SMAD2. This interaction between PRSS30 and SMAD2 allows PRSS30 to regulate the activity of the TGF-β pathway.

In addition to its role in TGF-β signaling, PRSS30 has also been shown to be involved in the development and progression of various diseases, including cancer. For example, it has been shown to be involved in the regulation of the angiogenesis of cancer cells. PRSS30 has also been shown to play a role in the regulation of cell signaling pathways that are associated with cancer, such as the PI3K/Akt signaling pathway.

As a result of its involvement in the TGF-β pathway and its potential role in the regulation of various diseases, PRSS30 has emerged as a promising drug target and biomarker. Studies have shown that inhibiting the activity of PRSS30 can lead to the inhibition of TGF-β signaling pathways and the inhibition of the development and progression of various diseases, including cancer.

In conclusion, PRSS30 is a protein that is characterized by its unique molecular structure and biology. It is involved in the regulation of TGF-β signaling pathways and has been shown to play a role in the development and progression of various diseases, including cancer. As a result, PRSS30 has emerged as a promising drug target and biomarker. Further studies are needed to fully understand the role of PRSS30 in the regulation of TGF-β signaling pathways and its potential as a drug target and biomarker.

Protein Name: Serine Protease 30, Pseudogene

The "PRSS30P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRSS30P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets